Skip to main content
SPRC
NASDAQ Life Sciences

SciSparc Registers Over 23 Million Shares for Resale, Enabling Massive Dilution

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.576
Mkt Cap
$2.506M
52W Low
$0.53
52W High
$11.109
Market data snapshot near publication time

summarizeSummary

SciSparc Ltd. filed an F-3 registration statement for the resale of up to 23,037,624 ordinary shares by selling shareholders, representing a substantial increase in potential outstanding shares and enabling significant selling pressure.


check_boxKey Events

  • Massive Share Registration for Resale

    SciSparc Ltd. registered 23,037,624 ordinary shares for resale by selling shareholders, with an aggregate offering price of approximately $14.4 million.

  • Enables Significant Dilution

    The registered shares represent over 450% of the company's currently outstanding shares, indicating substantial potential dilution for existing shareholders.

  • No Direct Proceeds to Company

    The company will not receive any proceeds from the sale of these shares by the selling shareholders, only from the potential cash exercise of associated warrants.

  • Follows Recent Dilutive Financings

    This registration follows the recent issuance of highly dilutive convertible notes and warrants (announced February 12 and 17, 2026) and shares issued for the Xylo acquisition (announced January 26, 2026).


auto_awesomeAnalysis

This F-3 filing by SciSparc Ltd. is a critical development, enabling the resale of a staggering 23,037,624 ordinary shares by selling shareholders. This volume represents a potential increase of over 450% to the current outstanding shares, signaling an impending and severe dilutive event for existing shareholders. The company will not receive any direct proceeds from these sales, only from the optional cash exercise of associated warrants. This registration formalizes the ability of investors from recent highly dilutive convertible note and warrant financings, as well as shares issued for the Xylo acquisition, to liquidate their holdings. Coming amidst the company's ongoing financial distress and Nasdaq delisting concerns due to insufficient stockholders' equity, this filing indicates a significant overhang on the stock and substantial selling pressure, further jeopardizing shareholder value.

At the time of this filing, SPRC was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.53 to $11.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SPRC - Latest Insights

SPRC
Apr 29, 2026, 4:20 PM EDT
Filing Type: 20-F
Importance Score:
9
SPRC
Mar 16, 2026, 8:21 AM EDT
Source: Reuters
Importance Score:
7
SPRC
Mar 12, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
8
SPRC
Mar 12, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
SPRC
Mar 10, 2026, 9:28 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
SPRC
Mar 02, 2026, 8:08 AM EST
Filing Type: 6-K
Importance Score:
9
SPRC
Feb 17, 2026, 5:27 PM EST
Filing Type: F-3
Importance Score:
9
SPRC
Feb 17, 2026, 4:01 PM EST
Filing Type: 6-K
Importance Score:
9
SPRC
Feb 12, 2026, 4:02 PM EST
Filing Type: 6-K
Importance Score:
9
SPRC
Feb 03, 2026, 4:36 PM EST
Filing Type: F-3
Importance Score:
9